

Office Action Mailed 10/12/06  
Amendment Filed February 22, 2007  
Page 2 of 8

RECEIVED  
CENTRAL FAX CENTER

FEB 22 2007


**IN THE CLAIMS**

Please amend the claims as follows:

1. (CURRENTLY AMENDED) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is water soluble and has a molecular weight ~~in the range of 100Da to 800~~ not greater than 60 kDa.
2. (CANCELED)
3. (ORIGINAL) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
4. (ORIGINAL) The composition of claim 1, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer
5. (ORIGINAL) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
6. (ORIGINAL) The composition of claim 1, further comprising a targeting ligand.

Office Action Mailed 10/12/06  
Amendment Filed February 22, 2007  
Page 3 of 8

7. (ORIGINAL) The composition of claim 4, comprising the structure:



wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

8. (CURRENTLY AMENDED) A method of treating an angiogenic disease comprising administering a composition of claim 1 to a mammal in need thereof, wherein the angiogenic disease is a solid tumor, a lymphoma, a leukemia, diabetic retinopathy or macular degeneration.


.0188415.3

Office Action Mailed 10/ 2/06  
Amendment Filed February 22, 2007  
Page 4 of 8

9. (CANCELED)
10. (CURRENTLY AMENDED) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is water soluble and has a molecular weight ~~in the range of 100 kDa to 800 kDa~~ not greater than 60 kDa.
11. (CANCELED)
12. (PREVIOUSLY PRESENTED) The method of claim 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
13. (ORIGINAL) The method of claim 10, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
14. (ORIGINAL) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.

Office Action Mailed 10/12/06  
Amendment Filed February 22, 2007  
Page 5 of 8

15. (ORIGINAL) The method of claim 10, comprising the structure:




wherein y is in the range of 0.04-20 and x is in the range of 80-99.96.

16. (ORIGINAL) The method of claim 15, wherein y is 5-10 and x is 90-95.
17. (ORIGINAL) An HPMA-TNP-470 conjugate comprising the structure:

10788415.3

Office Action Mailed 10/12/06  
 Amendment Filed February 22, 2007  
 Page 6 of 8



Wherein x is 90-95 and y is 5-10.